← All trials
NCT05917340
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 31, 2024
- Primary completion
- Sep 30, 2027
- Completion date
- Sep 30, 2027
- First posted
- Jun 23, 2023
- Last posted
- Dec 21, 2023
- Enrollment
- 372
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Indian Council of Medical ResearchLead sponsor
- Christian Medical College, Vellore, IndiaCollaborator
- Jawaharlal Institute of Postgraduate Medical Education and ResearchCollaborator
- National Institute for Research in Tuberculosis, Chennai, IndiaReponsible party - principal investigator
- Madras Medical CollegeCollaborator
- National Institute for Research in Tuberculosis, Chennai, IndiaSponsor investigator
- All India Institute of Medical SciencesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.